Nonalcoholic steatohepatitis (NASH) is an advanced form of fatty liver disease characterised by inflammation and liver cell damage, not just fat accumulation. Unlike simple fatty liver (NAFLD), NASH carries a significantly higher risk of progressing to cirrhosis, liver cancer, and liver failure. It develops in people who drink little to no alcohol and is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Early detection and lifestyle intervention are crucial to prevent irreversible liver damage. This article explains what NASH is, how it differs from fatty liver disease, its causes, symptoms, diagnosis, and evidence-based management strategies available in the UK.

What Is NASH and How Does It Differ from Fatty Liver Disease?

Nonalcoholic steatohepatitis (NASH) represents an advanced form of nonalcoholic fatty liver disease (NAFLD), characterised by hepatic inflammation and cellular injury in addition to fat accumulation. Whilst simple hepatic steatosis—the hallmark of NAFLD—involves fat deposition within liver cells without significant inflammation, NASH progresses beyond this to include hepatocyte ballooning, lobular inflammation, and often fibrosis. This distinction is clinically crucial, as NASH carries a substantially higher risk of progression to cirrhosis, hepatocellular carcinoma, and liver-related mortality.

The spectrum of NAFLD encompasses two principal entities: nonalcoholic fatty liver (NAFL), where steatosis occurs without significant inflammation or hepatocyte injury, and NASH, where inflammation and cellular damage are present. A proportion of individuals with NAFLD—often quoted as around 20%—will develop NASH, though precise UK prevalence figures remain challenging to establish due to the requirement for liver biopsy for definitive diagnosis. NICE recognises NAFLD and NASH as growing public health concerns, particularly given rising rates of obesity and type 2 diabetes mellitus.

Unlike alcoholic liver disease, NASH develops in individuals consuming little to no alcohol. The UK Chief Medical Officers advise that to keep health risks from alcohol low, it is safest not to drink more than 14 units per week on a regular basis for all adults. Diagnostic thresholds for excluding significant alcohol consumption vary across studies but typically require consumption below levels associated with alcoholic liver disease. The pathophysiology involves complex interactions between insulin resistance, lipotoxicity, oxidative stress, and inflammatory mediators. Whilst simple steatosis carries lower liver-related progression risk than NASH, it is not entirely benign and is associated with increased cardiometabolic risk. The inflammatory component in NASH triggers a cascade of fibrogenic responses that can ultimately lead to irreversible scarring. Early identification and intervention are therefore essential to prevent disease progression and preserve hepatic function.

Note: Some recent literature uses the terms metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) alongside NAFLD and NASH; these refer to the same conditions with updated nomenclature.

Causes and Risk Factors for Nonalcoholic Steatohepatitis

The development of NASH is multifactorial, with metabolic dysfunction serving as the primary driver. Insulin resistance represents the cornerstone pathophysiological mechanism, promoting hepatic de novo lipogenesis whilst impairing fatty acid oxidation and very-low-density lipoprotein secretion. This metabolic dysregulation creates an environment conducive to lipid accumulation and subsequent lipotoxicity, triggering inflammatory pathways and hepatocellular injury.

Key risk factors for NASH include:

• Obesity, particularly central adiposity, with body mass index (BMI) ≥30 kg/m² significantly increasing risk; however, steatotic liver disease can occur at normal BMI, especially in South Asian populations

• Type 2 diabetes mellitus, which is commonly associated with NASH

• Dyslipidaemia, especially elevated triglycerides and low high-density lipoprotein cholesterol

• Metabolic syndrome, encompassing hypertension, hyperglycaemia, dyslipidaemia, and central obesity

• Age over 50 years, with prevalence increasing substantially in older populations

• Genetic predisposition, including polymorphisms in genes such as PNPLA3, TM6SF2, and GCKR

Emerging evidence suggests that gut microbiome alterations and dietary patterns—particularly high fructose consumption and Western dietary habits—may contribute to NASH pathogenesis, though the precise mechanisms remain under investigation. Certain medications, including corticosteroids, tamoxifen, and some antiretroviral agents, have been associated with hepatic steatosis; whilst these drugs can cause steatosis, proven NASH is rarer and should be evaluated on a case-by-case basis.

Ethnicity influences NASH susceptibility, with individuals of Hispanic and South Asian descent demonstrating higher prevalence rates compared to those of African-Caribbean origin, even after adjusting for metabolic risk factors. Rapid weight loss and total parenteral nutrition may also precipitate or transiently worsen steatohepatitis. Understanding these risk factors enables targeted screening and early intervention strategies, particularly in high-risk populations attending primary care services across the UK.

Recognising Symptoms and Diagnosing NASH in the UK

NASH typically presents as an asymptomatic condition in its early stages, with most cases identified incidentally through abnormal liver function tests or hepatic imaging performed for unrelated indications. When symptoms do manifest, they are often nonspecific and may include persistent fatigue, right upper quadrant discomfort, or malaise. As fibrosis progresses towards cirrhosis, patients may develop more pronounced features such as jaundice, ascites, peripheral oedema, or signs of hepatic decompensation, though these represent advanced disease.

Physical examination may reveal hepatomegaly, though this finding lacks specificity. The absence of clinical stigmata does not exclude significant liver disease, emphasising the importance of biochemical and radiological assessment in at-risk populations.

Diagnostic approach in UK practice follows NICE guidance (NG49) and typically involves:

• Liver function tests, often showing elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST), though normal values do not exclude NASH

• Non-invasive fibrosis risk stratification in primary care using validated scores: FIB-4 (low risk if <1.3 in adults under 65 years or <2.0 in those aged 65 and over; high risk if >2.67) or NAFLD fibrosis score (low risk if <−1.455; high risk if >0.675)

• Enhanced Liver Fibrosis (ELF) test, recommended by NICE (DG34) for assessing fibrosis in NAFLD patients with indeterminate or high non-invasive scores

• Transient elastography, providing non-invasive assessment of hepatic stiffness as a surrogate marker for fibrosis (FibroScan is one example device)

• Ultrasound imaging, identifying hepatic steatosis though unable to distinguish NAFL from NASH

• Exclusion of alternative aetiologies, including viral hepatitis, autoimmune liver disease, haemochromatosis, and significant alcohol consumption

Liver biopsy remains the gold standard for definitively diagnosing NASH and staging fibrosis, though its invasive nature limits routine use. NICE recommends considering biopsy when non-invasive tests suggest advanced fibrosis or when diagnostic uncertainty exists.

Patients with persistently abnormal liver enzymes, metabolic risk factors, or evidence of hepatic steatosis on imaging should be referred for specialist hepatology assessment if non-invasive fibrosis markers suggest advanced fibrosis (e.g., ELF ≥10.51 or high transient elastography values) or if diagnostic uncertainty persists despite initial investigations.

Treatment Options and Lifestyle Changes for NASH

Currently, no pharmacological therapy holds UK marketing authorisation specifically for NASH, making lifestyle modification the cornerstone of management. NICE guidance (NG49) emphasises that treatment strategies should address underlying metabolic dysfunction whilst aiming to reduce hepatic inflammation and prevent fibrosis progression.

Weight reduction represents the most effective intervention, with evidence demonstrating that losing 7–10% of body weight can resolve NASH in a substantial proportion of patients and improve fibrosis scores. Gradual weight loss of 0.5–1 kg weekly is recommended, as rapid weight reduction may paradoxically worsen hepatic inflammation. Structured weight management programmes, including dietary counselling and behavioural support, should be offered through primary care or specialist services.

Dietary modifications should focus on:

• Reducing refined carbohydrates and added sugars, particularly fructose-containing beverages

• Adopting a Mediterranean-style diet rich in vegetables, whole grains, lean proteins, and healthy fats

• Limiting saturated fat intake

• Avoiding excessive caloric consumption and processed foods

Physical activity plays a crucial independent role beyond weight loss, with NICE recommending at least 150 minutes of moderate-intensity aerobic exercise weekly, supplemented by resistance training. Exercise improves insulin sensitivity, reduces hepatic steatosis, and may decrease inflammation even without significant weight reduction.

Pharmacological management targets associated metabolic conditions. Metformin, whilst improving insulin sensitivity, has not demonstrated consistent benefit for NASH histology. Pioglitazone may improve steatohepatitis and fibrosis in selected patients with type 2 diabetes or prediabetes, but its use for NASH is off-label in the UK and should be considered only under specialist advice after biopsy-proven NASH. Potential adverse effects include weight gain, fluid retention (which may precipitate or worsen heart failure), and increased fracture risk. Vitamin E (800 IU daily) may benefit non-diabetic NASH patients with biopsy-proven disease, but this is also off-label and should be initiated only by specialists; long-term safety data remain limited, with concerns about possible increased risks of haemorrhagic stroke and prostate cancer.

GLP-1 receptor agonists (such as semaglutide) are licensed in the UK for weight management (NICE TA875) and may improve NASH histology and steatosis, though this indication remains off-label. SGLT2 inhibitors may improve steatosis and ALT levels in patients with type 2 diabetes, though evidence is emerging and they are not licensed for NASH.

Statins are safe in NASH and should be prescribed for cardiovascular risk reduction according to NICE lipid modification guidance (NG238/CG181). Patients should be advised to avoid hepatotoxic substances, including alcohol consumption above 14 units per week and unnecessary medications. Bariatric surgery may be considered in accordance with NICE guidance (CG189): typically for adults with BMI ≥40 kg/m², or 35–39.9 kg/m² with significant comorbidities such as type 2 diabetes, when conventional weight loss strategies have failed. Specialist assessment is essential.

If you experience side effects from any medication, report them via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or by searching for 'Yellow Card' in the Google Play or Apple App Store.

Preventing Progression: Managing NASH and Liver Health Long-Term

Long-term management of NASH requires sustained lifestyle modification combined with regular monitoring to detect disease progression and manage complications. The primary goal is preventing advancement to cirrhosis, which occurs in a proportion of NASH patients—often quoted as around 10–20% over many years—with subsequent risks of hepatic decompensation and hepatocellular carcinoma.

Ongoing surveillance should include:

• Annual liver function tests and metabolic screening (HbA1c, lipid profile)

• Repeat non-invasive fibrosis assessment every 3 years in adults without advanced fibrosis (as per NICE NG49), or sooner if clinical deterioration occurs

• Ultrasound surveillance for hepatocellular carcinoma every six months in patients with established cirrhosis, following British Society of Gastroenterology guidelines

• Monitoring for complications of portal hypertension, including variceal bleeding and ascites

Optimising metabolic control remains paramount throughout follow-up. Tight glycaemic control in diabetic patients, blood pressure management (typically targeting <140/90 mmHg in most adults, with lower targets in specific circumstances such as diabetes with end-organ damage per NICE NG136 and NG28), and lipid optimisation all contribute to reducing cardiovascular risk—the leading cause of mortality in NASH patients. Regular medication review ensures that potentially hepatotoxic agents are avoided or used judiciously.

Patients should seek urgent medical attention if they develop new symptoms such as jaundice, abdominal swelling, confusion, vomiting blood, black tarry stools, or severe shortness of breath, as these may indicate hepatic decompensation. Call 999 or go to A&E immediately for severe symptoms such as vomiting blood or confusion; for other concerning symptoms, contact your GP for same-day assessment or call NHS 111 if you are unsure. Maintaining alcohol abstinence or consumption within the UK Chief Medical Officers' low-risk guideline (≤14 units weekly) is essential.

Vaccination is recommended for people with chronic liver disease, in line with the UK Green Book:

• Hepatitis A and B vaccination should be offered to all NASH patients, particularly those with advanced fibrosis or cirrhosis, as superimposed viral hepatitis can precipitate acute-on-chronic liver failure

• Pneumococcal vaccination (PPV and PCV as per schedule)

• Annual influenza vaccination

Emerging therapies targeting specific pathophysiological pathways—including farnesoid X receptor agonists, peroxisome proliferator-activated receptor agonists, and anti-fibrotic agents—are under investigation in clinical trials. Whilst none currently hold regulatory approval in the UK, they represent promising future treatment options. Patients interested in clinical trial participation should discuss this with their hepatology team.

Multidisciplinary care involving hepatologists, dietitians, diabetologists, and primary care physicians optimises outcomes and ensures comprehensive management of this complex, progressive condition.

Frequently Asked Questions